Notices of Intent to Revise and Pharmacopeial Forum-Related Notices

<90> Fetal Bovine Serum Quality Attributes and Functionality (posted 05–Feb–2021)
<661.1> Plastic Materials of Construction Notice of Intent to Revise (posted 18–Dec–2020)
<795> Pharmaceutical Compounding—Nonsterile Preparations (posted 01–Sep–2021)
<797> Pharmaceutical Compounding— Sterile Preparations (posted 01–Sep–2021)
Albuterol Inhalation Solution Notice of Intent to Revise (posted 16–Apr–2021)
Amantadine Hydrochloride Notice of Intent to Revise (posted 27–May–2020)
Aminocaproic Acid Oral Solution Notice of Intent to Revise (posted 31–Jul–2020)
Aprepitant Capsules, Galantamine Tablets, Praziquantel Tablets, and <1092> The Dissolution Procedure: Development and Validation Notice of Intent to Revise (posted 28–Aug–2020)
Azeotropic Isopropyl Alcohol Notice of Intent to Revise (posted 30–Apr–2021)
Baclofen Injection Notice of Intent to Revise (posted 30–Apr–2021)
Benztropine Mesylate Notice of Intent to Revise (posted 28–Dec–2020)
Benztropine Mesylate Notice of Intent to Revise (posted 30–Apr–2021)
Bifidobacterium bifidium Notice of Intenet to Revise (posted 27–Aug–2021)
Bifidobacterium longum subsp. longum Notice of Intent to Revise (posted 27–Aug–2021)
Bupropion Hydrochloride Notice of Intent to Revise (posted 19–Feb–2021)
Castor Oil Notice of Intent to Revise (posted 31–Jul–2020)
Codeine Phosphate Notice of Intent to Revise (posted 26–Mar–2021)
Copovidone Notice of Intent to Revise (posted 30–Apr–2021)
Deferred Proposal: General Notices and Requirements, 5.60.40 Impurities that are Unusually Toxic and/or Mutagenic (posted 30–Sep–2020)
Dextran 40 Notice of Intent to Revise (posted 30–Jul–2021)
Dextran 70 Notice of Intent to Revise (posted 30–Jul–2021)
Dextrose Injection Notice of Intent to Revise (posted 15–Oct–2021)
Diphenhydramine Hydrochloride Oral Powder Notice of Intent to Revise (posted 25–Sep–2020)
Clonidine Transdermal System Notice of Intent to Revise (posted 27–Mar–2020)
Gemfibrozil Tablets Notice of Intent to Revise (posted 28–Aug–2020)
Glucagon Notice of Intent to Revise (posted 01–Oct–2021)
Inhalation Product Monographs: Removal of Performance Tests (posted 25–Jun–2021)
Ipratropium Bromide Inhalation Solution (posted 28–May–2021)
Isopropyl Alcohol Notice of Intent to Revise (posted 30–Apr–2021)
Lactobacillus reuteri Notice of Intent to Revise (posted 27–Aug–2021)
Lacotbacillus rhamnosus Notice of Intent to Revise (posted 27–Aug–2021)
Lactobacillus Rhamnosus Notice of Intent to Revise (posted 20–Nov–2020)
Lauroyl Polyoxyglycerides Notice of Intent to Revise (posted 19–Feb–2021)
Magnesium Family of Monographs Notice of Intent to Revise (posted 27–Aug–2021)
Mesalamine Delayed-Release Tablets Notice of Intent to Revise (posted 30–Jul–2021)
Monographs with Postponed Content (posted 30–Jul–2021)
Orlistat Notices of Intent to Revise (posted 28–May–2021)
Orlistat Capsules Notice of Intent to Revise (posted 28–May–2021)
Pyrazinamide Notice of Intent to Revise (posted 19–Feb–2021)
Rotigotine Notice of Intent to Revise (posted 30–Jul–2021)
Sucrose Notice of Intent to Revise (posted 26–Feb–2021; updated 02–Apr–2021; updated 18–Jun–2021)
Talc Notice of Intent to Revise (updated 18–Dec–2020)
Technetium Tc 99m Monographs: Removal of Biological Tests (posted 30–Jul–2021)
Tetracycline, Tetracycline Hydrochloride and Tetracycline Hydrochloride Capsules Notice of Intent to Revise (posted 18–Dec–2020)